PTU - Polskie Towarzystwo Urologiczne
list of articles:

The presence and structure of circulating immune complexes in patients with renal cell cancer
Article published in Urologia Polska 2008/61/3.


Ryszard Go³da, Wojciech Jó¼wicki, Grzegorz Przybylski, Zbigniew Wolski, Jan Domaniewski, Ma³gorzata Wyszomirska, Jacek Micha³kiewicz
Department of Immunology, The Ludwik Rydygier Collegium Medicum in Bydgoszcz Nicolaus Copernicus University in Toruń
Department of Tumour Pathology, The F. £ukaszczyk Oncology Center in Bydgoszcz
Department of Respiratory Medicine and Tuberculosis, The Ludwik Rydygier Collegium Medicum in Bydgoszcz Nicolaus
Copernicus University in Toruń
Department of General, Oncologic and Pediatric Urology, Ludwik Rydygier Collegium Medicum in Bydgoszcz Nicolaus
Copernicus University in Toruń


renal cell carcinoma RCC circulating immune complexes RCC immunology cancer-derived atypical proteins


The aim of the study.

The detection, measurement and characterisation of circulating immune complexes (CIC) in tumour patients have shown both good and poor correlation with the progression of the disease. The origin of antigens consisting immune complexes in sera of examined cancer patients is unknown. Perhaps they are antigens specific for the cancer progress.

Material and methods.

The level as well as the characterisation (molecular mass) of the circulating immune complexes was estimated in the serum of 52 patients with renal cell cancer (G1 – 18, G2 – 21, and G3 grade – 13 patients), by means of polyethylene glycol (PEG) precipitation test.


The results were compared to the group of 45 healthy men. Elevated levels of CIC were observed in 44.2% of the patients with renal cell cancer. No seropositivity for CIC was observed in the control group. An increase in the seropositivity for CIC was observed in the patients with higher grade of renal cell cancer: the proportions of seropositive patients in the group of patients with G1, G2 and G3 phase of the disease were 27.7%, 52.4% and 53.8% appropriately. Molecular weight of the proteins of CIC was studied by
SDS/PAGE and showed 28 bands of MW 20 – 231 kDa. The CIC originated from patients with renal cancer consisted of the proteins which were absent in healthy persons.


Hence, the determination as well as the analysis of atypical proteins in the CIC, resulted from carcinogenesis, may improve a diagnostic procedure.


  1. Aziz M, Akhar S, Malik A, Evaluation of cell-mediated and circulating immune complexes as prognostic indicators in cancer patients. Cancer Detect Prev, 1998, 22, 87-99.
  2. Dass TK, Aziz M, Rattan A: Prognostic significance of circulating immune complexes in cancer patients. Jpn J Cancer Res, 1991, 82, 1284-1294.
  3. Gendek-Kuboak H, Grzegorczyk J, Genek EG, Kowalski ML, Bener J: Preoperative levels of serum immunoglobulins, circulating immune complexes and complement proteins in patients with different types neoplasms. Arch Immunol Ther Exp, 2001, 49, 89-95.
  4. Go³da R, Wolski Z, Wyszomirska-Go³da M et al: The presence and structure of circulating immune complexes in patients with prostate tumors. Med Sci Monit 2004, 10, 123-127.
  5. Go³da R, Wolski Z, Wyszomirska-Go³da M et al: Assay, isolation and characterisation of circulating immune complexes from serum of urinary bladder carcinoma patients. Polish Journal of Urology, 2005, 1, 43-46
  6. Kobayashi K, Umeda T, Akaza H, Niijima T, Aikawa T: Circulating immune complexes in patients with bladder cancer and other malignancies of the urogenital tract. Urol Int 1984, 39, 232-235.
  7. Mathin AA, Smoliagin AI: A comparative evaluation of the immune status of patients with squamous-cell cancer of the oral mucosa at different stages of combined treatment. Stomatologiia Mosk, 2000, 3, 29-32.
  8. Sakai S, Kato N, Ito Y et al: Detection of circulating immune complexes by polyethyleneglycol precipitation complement consumption test in urological malignant diseases. Hinyokika Kiy, 1984, 30, 1611-1617.
  9. Tomasevic Z, JEL S: Circulating immune complexes in advanced Hodgkin’s disease, qualitative analysis and prognostic significance. Arch Immunol Ther Exp, 2000, 48, 195-200.
  10. Vlock DR, Schantz SP, Fisher SG et al: Clinical correlates of circulating immune complexes and antibody reactivity in squamous cell carcinoma of the head and neck. J Clin Oncol 1993, 12, 2427-2433.
  11. Babaian RJ, Watson DA, Jones JM: Immune complexes in urine and serum of patients with bladder cancer. J Urol 1984, 131, 463- 466.
  12. Bhatti R, Shaw M, RAY P: Inhibition of sensitised leukocyte’s in vitro reactivity by circulating immune complexes in prostate cancer. Experientia 1987, 43, 916-917.
  13. Chester SJ, You-Pin LIM, Vezeridis MP, Hixon DC: Improved detection of the early stages of colon cancer by determining both free circulating and immune complex-bound antigens reactive with monoclonal antibody. Cancer Res 1994, 54, 3974-3978.
  14. Phillips TM: Immune complex assays, diagnostic and clinical application. Crit Rev Clin Lab Sci 1989, 27, 237-264.
  15. Skaarup P, Jensenius JC, Bramdslund I et al: Association of circulating immune complexes with glomerular proteinuria in patients with transitional cell carcinoma of the urinary bladder. Eur Urol 1984, 10, 249-253.
  16. Wong JM, Gupta RK, Morton DL: Serial determinations of melanoma tumour-associated antigen and antibody in-patients with stage I melanoma. Arch. Surg 1986, 121, 1342.
  17. Mavlight GM, Stuckey S: Colorectal carcinoma. Evidence for circulating CEA-anti-CEA complexes. Cancer 1983, 52, 146.
  18. Bartoloni C, Guidi L, Pili R et al: Assay, isolation and characterisation of immune complexes from serum of gastrointestinal cancer, stage III and IV melanoma and chronic inflammatory bowel disease patients. Oncology 1993, 50, 27-34,
  19. Habal N, Gupta RK, Bilchik AJ et al: TA90-IC, a new marker for advanced colon cancer. Ann Surg Oncol 2000, 7, 352-356.
  20. Wiederkehr F, Bueler MR, Vonderschmitt DJ: Chromatographic and electrophoretic studies of circulating immune complexes in plasma. J Chromatogr 1991, 566, 77-87.
  21. Gupta RK, Morton DL: Prognostic value of a 90kD subunit containing glycoprotein tumor-associated antigen specific immune complexes in lung cancer patients. Dis Markers 1994, 12, 51-61.
  22. Hoffman WL, Kelly PJ, Ruggles AO: Characterization of immune complex components by dot blot analysis. Analytical Biochemistry 1992, 207, 44-50.
  23. Nelsen MB, Nyhus JK, Oravecz-Wilson KI, Barbera-Guille ME: Tumor cells express FcgammaRI which contributes to tumor cell growth and a metastatic phenotype. Neoplasia 2001, 3, 115-125.
  24. Theofilopoulos AN: Immune complexes in cancer. N Engl J Med 1982, 307, 1208-1209.
  25. Go³da R, Wyszomirska-Go³da M, Przybylski G, Jó¼wicki W: Assay, isolation and characterisation of circulating immune complexes from serum of patients with lung cancer in the city population. Polish Journal of Environmental Study 2005, 14, 114-118.
  26. Haskova V, Kaslik J, Riha I et al: Simple method of circulating immune complex detection in human sera by polyethyleneglycol precipitation. Z Immun Forsch 1978, 154, 399.
  27. Madaliński K, Burczyńska B, Heermann H, Uy A: Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus. Clin Exp Immunol 1991, 84, 493-500.
  28. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 22, 680-685.
  29. De Moreno MR, Smith JF, Smith RV: Silver staining of proteins in polyacrylamide gels. Increased sensitivity through a combined coomassie bluesilver stain procedure. Analytical Biochemistry 1985, 151, 466-470.


Source of support: This work was supported in part by a research grant
from The Ludwik Rydygier Collegium Medicum in Bydgoszcz Nicolaus Copernicus
University in Torun, Poland (BW 127/97, BW 44/2007).
Acknowledgment. To Kazimierz Madaliński, Professor, for English revision of
the manuscript.